

**SCRIPPS RESEARCH
INSTITUTIONAL BIOSAFETY COMMITTEE
MEETING MINUTES
April 8, 2026**

I. MEETING

The Institutional Biosafety Committee (IBC) of Scripps Research held a meeting via videoconference April 8, 2026, commencing at 2 p.m. Pacific Time. The meeting was held pursuant to notice duly given, and a quorum was present.

Committee Members Present		Committee Members Absent	Others Present
Juan Carlos de la Torre	Michael Bobardt	Jim Gohres	Amy Green
Mychelle Fernandez	Cheryl Andreoli	Lorena Garcia Menendez	
Elyse Walk	Elizabeth Montano		
Roberto Aiolfi	Case McNamara		
Raphael Park	Steven Robert Head		
Smita Chopade	Stephen Munday		

I. REVIEW OF PREVIOUS MEETING MINUTES

The Committee voted unanimously to approve the minutes of the March 11, 2026 IBC Meeting.

II. ANNOUNCEMENTS

Annual training for IBC members will take place at the May 13th meeting.

III. BIOSAFETY OFFICER & IBC ADMINISTRATOR'S REPORT

None.

IV. CONFLICT OF INTEREST

Juan de la Torre will abstain from voting on his protocol #04-08-26-01. Case McNamara will abstain from voting on protocol #04-08-26-06 for the Bakowski lab. Roberto Aiolfi will abstain from voting on protocol #04-08-26-02 for Mosnier lab.

V. REVIEW OF PROTOCOLS

Summary of Discussions: Summaries of each research proposal were thoroughly discussed, including but not limited to: agent characteristics; types of manipulations planned; sources of the nucleic sequences; nature of the nucleic acid sequences; hosts and vectors to be used; whether any attempt will be made to obtain expression of a transgene, and if so, the function of the protein that will be produced. The committee assessed key risks presented by the research and confirmed the appropriate biocontainment level for the conduct proposed.

FULL COMMITTEE REVIEW

RENEWALS

1. IBC Protocol #: 04-08-26-01, de la Torre, Juan Carlos
Title of Study: Drug repurposing for antivirals against monkeypox infections
Department: Immunology & Microbiology
Primary Reviewer: Michael Bobardt
Secondary Reviewer: Mychelle Fernandez

NIH Guidelines: III-D-1
Agents/Materials: Recombinant vaccinia virus, Western Reserve (WR) strain, Monkeypox USA-2003 (NR-2500) Clade II, human cell lines, non-human primate cell lines.
Biosafety Level: BSL-2+
Animal work: ☐ Yes ☒ No
Biosafety Inspection: Inspection of IMM 319 completed on 3/19/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

BSA's needs to be changed from Bovine Serum Albumins to Broad Spectrum Antivirals. Under regulatory compliance, add Monkeypox USA-2003 (NR-2500) Clade II.

Study Design/Project Description

The BSL-3 doorcard needs to be attached.

Exposure Control

BSL-3 training for specific lab members needs to be clarified.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

2. IBC Protocol #: 04-08-26-02, Mosnier, Laurent
Title of Study: Experimental and therapeutic approaches to modify the coagulation pathway
Department: Translational Medicine
Primary Reviewer: Cheryl Andreoli
Secondary Reviewer: Smita Chopade
NIH Guidelines: III-D-1, III-D-2, III-D-4-b, III-E-3
Agents/Materials: Retroviral vector, SARS-CoV-2, Lymphocytic choriomeningitis virus, E.coli DH5α, AAV8-FVIII, human cell lines, human primary cells.
Biosafety Level: BSL-2, ABSL-2
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of IMM 315-316 completed on 3/10/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

The IACUC protocol link needs to be updated.

Location of Study

The presence of a biosafety cabinet needs to be confirmed or refuted for the ABSL2 rooms listed.

Study Design/Project Description

Door cards need to be uploaded.

DURC

The 'result of assessment' should be neither.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

3. IBC Protocol #: 04-08-26-03, Chanda, Sumit

Title of Study: Global innate immune response to HIV-1 infection and clinical reactivation of latent HIV for eradication of HIV
Department: Immunology & Microbiology
Primary Reviewer: Case McNamara
Secondary Reviewer: Roberto Aiolfi
NIH Guidelines: III-D-1, III-D-2, III-E-1
Agents/Materials: HIV-1, Lentiviral vector, Vibrio cholerae, E. coli, retroviral vector, human cell lines, non-human primate cell lines, human primary cells
Biosafety Level: BSL-2+
Animal work: ☐ Yes ☒ No
Biosafety Inspection: Inspection of IMM 212, 115C, MBB 20A completed on 2/12/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

Whether an IACUC study is active or not needs to be confirmed. If there is an active study, the active protocol needs to be linked.

Personnel

Steven can be removed.

Location of Study

Clarification on whether CALIBR is a location of study is needed. The microscopy core needs to be changed to BSL-1.

Infectious Agents

Retroviral vectors need to be changed to risk group 2.

Vertebrate or Invertebrate Animals

This section needs to be updated to align with the information in the 'General Information' tab.

Study Design/Project Description

The volume of Vibrio cholera used needs to be added.

Regulatory Assessment

The Cal/OSHA Aerosol Transmissible Diseases Standard box needs to be selected.

Risk Assessment

Flow cytometry needs to be selected.

Exposure Control

Aerosol transmissible diseases training must be checked.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

4. IBC Protocol #: 04-08-26-04, Hang, Howard
Title of Study: Microbial Regulation of Immune Cell Function
Department: Immunology & Microbiology
Primary Reviewer: Smita Chopade
Secondary Reviewer: Cheryl Andreoli
NIH Guidelines: III-D-4-a
Agents/Materials: Mouse Retrovirus, E. coli, mouse lentivirus, human cell lines
Biosafety Level: BSL-2, ABSL-1
Animal work: ☒ Yes ☐ No
Biosafety Inspection: Inspection of IMM 115 completed on 3/12/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

BSL-1 and BSL-2 activities need to be separated more clearly.

Location of Study

Clarification on the presence of a biosafety cabinet in the BSL-1 space is needed.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

5. IBC Protocol #: 04-08-26-05, Boger, Dale
Title of Study: Toxicity Studies of Vancomycin and Vancomycin Analogues
Department: Chemistry
Primary Reviewer: Raphael Park
Secondary Reviewer: Case McNamara
NIH Guidelines: N/A
Agents/Materials: Staphylococcus aureus, Acinetobacter baumannii, Pseudomonas aeruginosa, Klebsiella pneumoniae, Enterococcus faecalis, Enterococcus faecium, human cell lines
Biosafety Level: BSL-2
Animal work: ☐ Yes ☒ No
Biosafety Inspection: Inspection of BCC 462 completed on 3/16/26.
Training: Training verified and on record.

The following action items were identified as needing to be updated on the protocol:

General Information

A change of title to more closely reflect the research has been requested.

A broad picture statement of research is needed.

Infectious Agents

A description of the method of growing and processing cultures, to include the use of sealed rotor cups, is needed.

Risk Assessment

Additional aerosol generating procedures need to be checked here to reflect the growth of liquid bacterial cultures.

Exposure Control

A review of the engineering equipment used is needed.

Review outcome: Not approved; Revisions to be re-reviewed by designated member review.

6. IBC Protocol #: 04-08-26-06, Bakowski, Malina

Title of Study: Influenza Drug Discovery

Department: Biology- Calibr

Primary Reviewer: Roberto Aiolfi

Secondary Reviewer: Michael Bobardt

NIH Guidelines: III-D-2

Agents/Materials: Influenza A virus, Influenza B virus, Recombinant PA-I38T Influenza, Recombinant WT Influenza, human cell lines, non-human primate cell lines.

Biosafety Level: BSL-2, ABSL-2

Animal work: ☒ Yes ☐ No

Biosafety Inspection: Inspection of Calibr 124 completed on 11/25/25.

Training: Pending training.

The following action items were identified as needing to be updated on the protocol:

General Information

The current AUP needs to be linked.

Vertebrate or Invertebrate Animals

Mouse homogenates need to be added to the list of items collected post infection.

Study Design/Project Description

The ABSL2 door card needs to be attached.

Review outcome: Conditional approval; full approval granted upon completion of the above listed action items.

BIOSAFETY REVIEW

1. IBC Protocol #: 12-10-25-05, Hang, Howard

Title of Study: Immunotherapy Studies

Department: Immunology & Microbiology

NIH Guidelines: III-D-2, III-D-4-b

Agents/Materials: Clostridium scindens, Clostridium sporogenes, E. coli, Enterococcus spp., Staphylococcus aureus, Weissella cibaria, human cell lines.

Biosafety Level: BSL-2, ABSL-2

Animal work: ☒ Yes ☐ No

Training: Training verified and on record.

REVIEW OUTCOME: Approved.

2. IBC Protocol #: 10-08-25-05, Petrascheck, Michael

Title of Study: Developing compounds that delay cellular senescence and protect from other age-associated toxicities

Department: Molecular & Cellular Biology

NIH Guidelines: III-D-1, III-D-2

Agents/Materials: Adeno-associated virus, E. coli, lentivirus, human cell lines.

Biosafety Level: BSL-2+, ABSL-1

Animal work: ☒ Yes ☐ No

Training: Training verified and on record.

REVIEW OUTCOME: Approved.

3. IBC Protocol #: 11-08-17-02, Lipton, Stuart

Title of Study: Stereotaxic Transcranial Injection of Lentiviral Constructs and Live Cells into the Mouse Brain

Department: Molecular & Cellular Biology

NIH Guidelines: III-D-1, III-D-4-a, III-D-4-b

Agents/Materials: Lentivirus, lipopolysaccharide, human primary cells.

Biosafety Level: BSL-2, ABSL-1

Animal work: ☒ Yes ☐ No

Training: Training verified and on record.

REVIEW OUTCOME: Approved.

4. IBC Protocol #: 09-11-19-05, Law, Mansun

Title of Study: Viral Studies

Department: Immunology & Microbiology

NIH Guidelines: III-D-1, III-D-2, III-D-3, III-D-4-b, III-E-1

Agents/Materials: Adeno-associated virus, E. coli, HCV Pseudo virus particles, Hepatitis C Virus pseudotyped Vesicular Stomatitis Virus, Hepatitis D Virus, Hepatitis B Virus, HIV Pseudovirus, Lentivirus, single cycle Vesicular Stomatitis Virus, Vaccinia Virus, Zika virus, human cell lines, non-human primate cell lines.

Biosafety Level: BSL-2+, ABSL-2

Animal work: ☒ Yes ☐ No

Training: Training verified and on record.

REVIEW OUTCOME: Approved.

VI. ADJOURNMENT

The next scheduled IBC meeting is **Wednesday, May 13, 2026**, via Teams at 2:00 PM. If full committee review protocols are not received by the next deadline date and there are no agenda items for full committee discussion, the meeting will be canceled. Members will be notified via e-mail of meeting cancellations one week before the scheduled meeting.